Evidence map›Paper›PMID 40897819›Full record

ArticleBritish journal of cancer2025

Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.

S Van Dam, D Krijgsman, E Küçükköse, M E L Verdonschot, M Amini, W A M Blokx, M J M Van Eijs, R J Verheijden, O Kranenburg, K P M Suijkerbuijk and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S Van Dam *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
D Krijgsman *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
E KüçükköseLaboratory Translational Oncology, Division of Imaging and Cancer, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-8983-9464
M E L VerdonschotCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
M AminiCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0009-0009-8301-0178
W A M BlokxDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
M J M Van EijsCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-9763-6704
R J VerheijdenDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1966-1063
O KranenburgLaboratory Translational Oncology, Division of Imaging and Cancer, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-2112-4390
K P M SuijkerbuijkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-3604-5430
J H W LeusenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Y VercoulenCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. y.vercoulen@umcutrecht.nl.ORCID http://orcid.org/0000-0002-5060-2603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibition (ICI) significantly improves the survival of metastatic melanoma patients; however, a substantial proportion of patients does not respond to these breakthrough therapies.

methodsTo improve our understanding of this response variability, we developed high-plex panels for protein imaging of a discovery cohort and validation with RNAseq analyses to examine myeloid and T-cell subsets in pre-anti-PD-1-treatment samples of 14 metastatic melanoma patients (7 responders and 7 non-responders).

resultsWe demonstrate that a higher abundance of circulating monocyte-derived macrophages (MDMs) and cytotoxic T-cell subsets in the tumor microenvironment (TME) at baseline distinguishes metastatic melanoma patients with a favorable response to anti-PD1 treatment from non-responders, who featured co-localization of suppressive macrophages (M2) and T-cells. Additionally, MDMs expressed high levels of immune checkpoints, and MDM infiltration into the TME was linked to both ICI response and survival.

conclusionThese findings highlight the potential of MDM infiltration as a predictive biomarker for ICI response in metastatic melanoma.

Indexed as

Immune Checkpoint InhibitorsMelanomaMyeloid CellsProgrammed Cell Death 1 ReceptorT-Lymphocyte SubsetsTumor MicroenvironmentAdultAgedFemaleHumansMacrophagesMaleMiddle AgedNeoplasm MetastasisImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID40897819
PMCPMC12572286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.